-
XtalPi Forms Strategic Partnership with ABB Robotics to Automate Lab Workstations in China
•
Sino-US AI drug development company XtalPi (QuantumPharm, HKG: 2228) has entered into a strategic partnership with Switzerland-based ABB Robotics, aiming to manufacture a series of automated laboratory workstations within China. These workstations, featuring ABB’s GoFa robots, are anticipated to enhance the productivity of R&D processes across biopharmaceuticals, chemical engineering, chemistry,…
-
InnoCare Pharma Receives US FDA IND Approval for BCL2 Inhibitor ICP-248
•
InnoCare Pharma (HKG: 9969; SHA: 688428), a China-based pharmaceutical company, has announced that it has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for its B-cell lymphoma-2 (BCL2) inhibitor, ICP-248. The drug is set to enter a Phase I trial to assess safety, tolerability,…
-
Chipscreen NewWay Biosciences Initiates Phase I Trial for PD-1/CD40 Bispecific Antibody Candidate NWY001
•
China-based Chengdu Chipscreen NewWay Biosciences Co., Ltd has announced that the first patient has been dosed in a Phase I clinical trial for its investigational PD-1/CD40 bispecific antibody (BsAb) candidate, NWY001. The multi-center, non-random, open-label trial is conducted under the leadership of Sun Yat-Sen University Cancer Center, with objectives to…
-
Mindray Partners with WakeMed for Comprehensive Patient Monitoring Solutions
•
Shenzhen-based medtech company Mindray has announced a procurement agreement with WakeMed Health & Hospitals in North Carolina, USA, for its patient monitoring systems. Under the terms of the deal, WakeMed will implement Mindray’s BeneVision Distributed Monitoring System (DMS) and BeneVision N-Series Patient Monitoring Systems across three of its hospitals. The…
-
3D Medicines Secures Registration for Envafolimab in Macau for Advanced Solid Tumors
•
3D Medicines (HKG: 1244), a China-based oncology specialist, has announced the registration of its PD-L1 monoclonal antibody (mAb) envafolimab in Macau. The approval designates envafolimab for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors. Envafolimab is notable for being the world’s first…
-
Hope Medicine Initiates Phase II Trial for HMI-115 in Endometriosis Treatment
•
Hope Medicine Inc., based in China, has announced the first patient dosing in a global Phase II clinical trial for its monoclonal antibody (mAb) HMI-115, which targets the prolactin receptor (PRL R). The study aims to evaluate HMI-115 as a treatment for endometriosis in Chinese patients. In April 2019, Hope…
-
Neuboron Medtech Secures Clinical Trial Approval for First BNCT Drug in China
•
Neuboron Medtech Ltd., based in China, has received clinical trial approval for its borofalan (10b) injection, as indicated on the website of China’s Center for Drug Evaluation (CDE). This marks the first boron neutron capture therapy (BNCT) to enter regulatory studies in China and the second globally, targeting recurrent malignant…
-
AstraZeneca China Announces Leadership Changes and New Biopharmaceutical Unit
•
AstraZeneca (AZ, NASDAQ: AZN)’s China unit is set to undergo significant organizational changes, including the establishment of a new business department and three C-suite appointments, as reported by local media. Chen Kangwei, currently the General Manager of AstraZeneca’s China oncology division, will relocate to Singapore for family reasons, taking on…
